Bilateral Exablate thalamotomy for Essential Tremor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of staged bilateral Exablate thalamotomy in patients who have previously undergone unilateral treatment for Essential Tremor. It is a multicenter, randomized, controlled, and blinded study that compares the outcomes of patients receiving the bilateral procedure against those continuing with standard medical treatment. The primary focus is on measuring tremor reduction, functional impairment, quality of life, and safety through adverse event monitoring over a six-month period. Participants will be assessed for their ability to communicate sensations during the procedure and must meet specific imaging criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Men and women with an age of 18 years or older (according to local labeling).
2. Willing to participate in the study (i.e., signed ICF). (Willing to be randomized).
3. Patient is able to undergo a high-resolution Computerized Tomography (CT) scan.
4. Patient is able to fit into MRI unit and comply with all contraindications for the specific magnetic resonance (MR) system including and limited to contrast medium should there be needed.
5. The thalamus, sub-thalamus and the pallidum must be apparent on MR imaging.
6. Patient is able to communicate sensations to the physician during the procedure; Procedure does not require general anesthesia.
7. Patient must be able to use the Stop Sonication button freely.
8. Patient willing to have their head shaved prior to the actual treatment.
9. Patient has no history for claustrophobia which is not responding to medications.
10. ET patients who are eligible for second side staged bilateral Exablate thalamotomy treatment (according to local labeling). Time since first intervention is at least 9 months.
11. Available tremor assessment prior to the unilateral Exablate thalamotomy.
12. Patients randomized to the study, irrespective of group allocation should be willing and able to remain in the study for at least 6 months and able to complete the required assessments.

Exclusion Criteria:

1. Subject experienced any non-transient neurological event or worsening following the previous Exablate procedure.
2. Patients with MRI related contraindications (e.g. presence of metallic implants incompatibility with MRI, severe claustrophobia, reaction to contrast medium).
3. Patients in whom it is not possible to avoid energy absorbing structures or sensitive tissues (e.g., skull implants, surgical clips, shunts, electrodes, dura patch, skull patch, electrodes, etc.) from the path of the ultrasound beam.
4. Patients with concurrent active infections disease and/or severe allergies with fever.
5. Patients that have been diagnosed with brain tumors or a vascular anomaly.
6. Patients with a history of seizures, brain hemorrhages, stroke within the past year, or any coagulopathy.
7. Patients under anticoagulants and/or anti-platelets drugs known to increase bleeding risk within the duration defined by the half-life of the specific drugs.
8. Patient that has been given any contrast agent (e.g., CT, MRI), within 24 hours before treatment
9. Severe unstable hypertension that cannot be controlled by medications (diastolic Blood Pressure \> 100 on medication).
10. Patients with unstable cardiac status.
11. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse.
12. Cerebrovascular disease (multiple CVA or CVA within 6 months).
13. Patients with risk factors for intraoperative or postoperative bleeding.
14. Imaging shows abnormal finding in CT or/and MRI (e.g., brain tumor, brain vascular malformation, shunt, etc.).
15. Patient has physical subscale score ≥ 16.5 on the Dysphagia Handicap Index or has been diagnosed with dysphagia.
16. Patient with cognitive impairment.
17. Patient with clinically significant abnormal speech function as determined by a speech pathologist.

Where it's running

• Turku University Hospital
  Turku, Finland Recruiting
• Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)
  Kiel, Germany Recruiting
• Fondazione IRCCS Istituto Neurologico Carlo Besta
  Milan, Italy Recruiting
• Germans Trias i Pujol Hospital
  Badalona, Spain Recruiting
• HM CINAC- Hospital Universitario HM Puerta del Sur
  Móstoles, Spain Recruiting
• Clinica Universidad de Navarra
  Pamplona, Spain Recruiting

Study contacts

• Principal investigator: Günther Deuschl — Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)
• Study coordinator: Pascalle Reiters
• Email: pascaller@insightec.com
• Phone: +31 653726776

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Encora X1 in Daily Life for Essential Tremor

  This real-world study tests how the Encora X1 wrist device affects day-to-day activities for adults with essential tremor over three years.

  Recruiting Encora, Inc. · Boston, Massachusetts · NCT07911488

• Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment

  This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07868614

• Microelectrode-based brain stimulation for Parkinson’s and essential tremor

  This early feasibility test checks a new microelectrode-based brain stimulation method in adults with Parkinson’s disease or essential tremor who are already getting deep brain stimulation implants.

  Recruiting Lund University · Lund, Skåne County · NCT07820189

• Non-Invasive Nerve Stimulation for Essential Tremor: Long-Term Safety and Effectiveness

  This study tests whether a non-invasive stimulation device called TAPS helps reduce tremor in adults with essential tremor over a long period.

  Recruiting Ruijin Hospital · Shanghai · NCT07774598

• Low Intensity Focused Ultrasound for Essential Tremor in Adults

  This early-stage, open-label study tests whether repeated low-intensity focused ultrasound can safely and briefly modulate tremor in people with essential tremor.

  Recruiting Early Phase 1 University of California, Los Angeles · Los Angeles, California · NCT07599592

• Closed-loop TMS to reduce tremor

  This trial tries phase-locked transcranial magnetic stimulation (TMS) to reduce tremor in people with essential tremor or Parkinson's disease.

  Recruiting University of Oxford · Oxford, Oxfordshire · NCT07574164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.